Currently, p53 status does not have an established role in the diagnostic work up of HNSCC, although TP53 mutations have been identified in over 50% of head and neck carcinomas and their presence was associated with adverse outcomes [28]. This evidence concerns the gene TP53 and head and neck carcinoma.